EUROPEAN COMMISSION HEALTH AND CONSUMERS DIRECTORATE-GENERAL. EudraLex The Rules Governing Medicinal Products in the European Union

Similar documents
COMPUTERISED SYSTEMS

References Concept. Principle. EU Annex 11 US FDA , (g), (i), 11 Orlando Lopez 2/15/11. Old Annex 11.

EUROPEAN COMMISSION ENTERPRISE AND INDUSTRY DIRECTORATE-GENERAL. EudraLex The Rules Governing Medicinal Products in the European Union

EU Annex 11 US FDA , (g), (i), 11 Orlando López 09-APR

EU Annex 11 US FDA 211, 820, 11; other guidelines Orlando López 11-MAY-2011

Computer System Validation Perform a Gap Analysis of your CSV Processes

CUSTOMER AND SUPPLIER ROLES AND RESPONSIBILITIES FOR 21 CFR 11 COMPLIANCE ASSESSMENT. 21 CFR Part 11 FAQ. (Frequently Asked Questions)

EU GMP - Annex 11 Computerised systems Versione corrente Nuova versione per commenti (emessa 8 aprile 2008)

Regulatory Overview Annex 11 and Part 11. Sion Wyn Conformity +[44] (0)

Data Integrity: Production Environment

Computerised System Validation

EU Annex 11 update. An ISPE interpretation

PTC s Windchill Product Lifecycle Management (PLM) System Facilitates Part 11 / Annex 11 Compliance

Oracle Tech Cloud GxP Position Paper December, 2016

Computerised Systems. Inspection Expectations. Paul Moody, Inspector. 18/10/2013 Slide 1. ISPE GAMP COP Ireland Meeting, Dublin, 17 th October 2013

Cross-walk between EU Annex 11 and US FDA 211, 820, 11; other guidelines and regulations Orlando López Rev19Dec14

EUROPEAN COMMISSION ENTERPRISE AND INDUSTRY DIRECTORATE-GENERAL. EudraLex The Rules Governing Medicinal Products in the European Union

Enterprise and Industry Directorate-General European Commission B-1049 Brussels Belgium BY TO and

EUROPEAN COMMISSION HEALTH AND CONSUMERS DIRECTORATE-GENERAL. EudraLex. The Rules Governing Medicinal Products in the European Union

SIMATIC IT. SIMATIC IT R&D SUITE V7.1 Compliance Response ERES. Introduction 1. The Requirements in Short 2

EUROPEAN COMMISSION HEALTH AND CONSUMERS DIRECTORATE-GENERAL. EudraLex. The Rules Governing Medicinal Products in the European Union

Summary of Significant Changes. Policy

Cross-walk between EU Annex 11 and US FDA 211, 820, 11; other guidelines and regulations Orlando López Rev05MAR15

Computerised Systems. Alfred Hunt Inspector. Wholesale Distribution Information Day, 28 th September Date Insert on Master Slide.

EUROPEAN COMMISSION ENTERPRISE AND INDUSTRY DIRECTORATE-GENERAL

Cross-walk between EU Annex 11 and US FDA 211, 820, 11; other guidelines and regulations Orlando López Rev11AUG16

System Requirements (URS)

EUROPEAN COMMISSION DIRECTORATE-GENERAL FOR HEALTH AND FOOD SAFETY. EudraLex. Volume 4

Compliance Response Electronic Records / Electronic Signatures for COMOS V10.0

Compliance Response Electronic Records / Electronic Signatures (ERES) for SIMATIC PCS 7 V8.1

Clarity CDS since version 7.2 supportive tools for compliance with Title 21 CFR Part 11, EudraLex Chapter 4, Annex 11 and other similar legislation

White paper: Code of GMP Chapter 4 Documentation - PIC/S versus EU

Cross-walk between EU Annex 11 and US FDA 211, 820, 11; other guidelines and regulations Orlando López Rev22APR16

ISPE NORDIC COP CLEAN UTILITIES SEPTEMBER TUUSULA FINLAND. Timo Kuosmanen STERIS Finn-Aqua

Implement Effective Computer System Validation. Noelia Ortiz, MME, CSSGB, CQA

Annex IV to guidance for the conduct of good clinical practice inspections sponsor and CRO

Working Party on Control of Medicines and Inspections. Final Version of Annex 16 to the EU Guide to Good Manufacturing Practice

Contents. Contents (13) 1 Qualification (21)

Electronic Systems - Regulators Observations

GUIDANCE NOTE 37 MEDICAL GASES DATA INTEGRITY

COMPUTER SYSTEMS VALIDATION

DATA INTEGRITY ASSURANCE AS KEY FACTOR FOR SURVIVING CORPORATE AUDITS AND REGULATORY INSECTIONS

GAMP5 Validation for Dynamics 365

Regulations and guidance for the pharmaceutical industry

General European OMCL Network (GEON) QUALITY MANAGEMENT DOCUMENT

Beamex CMX Calibration Software and GAMP - Good Automated Manufacturing Practices

Data Integrity Through the Life Cycle Balancing Quality and Innovation. Sion Wyn Conformity +44 (0)

Validation of MES and Manufacturing Automation systems

(Information) INFORMATION FROM EUROPEAN UNION INSTITUTIONS, BODIES, OFFICES AND AGENCIES EUROPEAN COMMISSION

EUROPEAN COMMISSION HEALTH AND CONSUMERS DIRECTORATE-GENERAL. This document is for consultation until 11 December 2015

GAMP Guideline & Validation Documentation

Good Laboratory Practice GUIDELINES FOR THE VALIDATION OF COMPUTERISED SYSTEMS. Release Date:

Data Integrity Why is it important? DADM Conference - 22 August 2017

Brussels, C(2017) 8179 final. Guidelines

New GMPs for Active Substances & Excipients. Presented by Eoin Hanley 4 July, 2016

COMMISSION RECOMMENDATION. of XXX. on the audits and assessments performed by notified bodies in the field of medical devices

Guideline on. Plasma Master File (PMF) And. Vaccine Antigen Master File (VAMF) Second Step

The European Medicines Agency Inspections ANNEX IV TO PROCEDURE FOR CONDUCTING GCP INSPECTIONS REQUESTED BY THE EMEA:

GMP GUIDELINES. GMP Guides from Industry Organisations. FDA cgmp WHO GMP. cgmp Guide Drugs 21 CFR 210 GAMP. ISPE Technical Guides

Ensure Data Integrity Compliance Enterprise-Wide

Current Trends in Data Quality and Integrity Issues in Inspections and Risk Based Approach to Investigations; EU perspective

EUROPEAN INDUSTRIAL PHARMACISTS GROUP. Guidance on CPD for QUALIFIED PERSONS

OECD Working Group on Good Laboratory Practice. Template for submission of comments on draft GLP Guidance Documents. Instructions for Use

EudraLex. Part I1 Chapter 6: Quality Control

EUROPEAN COMMISSION HEALTH AND CONSUMERS DIRECTORATE-GENERAL

PHARMACEUTICAL INSPECTION CONVENTION PHARMACEUTICAL INSPECTION CO-OPERATION SCHEME. PI July 2018

Documenta tion and Records

EUROPEAN COMMISSION ENTERPRISE AND INDUSTRY DIRECTORATE-GENERAL. EudraLex. The Rules Governing Medicinal Products in the European Union Volume 4

Stakeholder Meeting, 17 June 2011, EMA, London. Fergus Sweeney, Head, Compliance and Inspections, European Medicines Agency

EUROPEAN COMMISSION HEALTH AND CONSUMERS DIRECTORATE-GENERAL

Impacto de las Nuevas Tendencias Regulatorias en la Producción de Parenterales. Innovacion en Packaging Primario

European Union (EU) Regulatory Trends in GMP. Clive Brading Tianjin, China September 23, 2009

Develop a Roadmap for the Implementation of a Global CSV Program. Eileen Cortes April 26, 2017

MINISTRY OF HEALTH ORDINANCE

GUIDELINES ON THE PRINCIPLES OF GOOD DISTRIBUTION PRACTICE OF ACTIVE SUBSTANCES FOR MEDICINAL PRODUCTS FOR HUMAN USE

Good Documentation Practices. Documentation Requirements For Regulated Environments

Compliance & Validation Validation of Software-as-a-Service (SaaS Solutions)

[ WHITE PAPER ] A Basic Overview: Meeting the PIC/S Requirements for a Computerized System INTRODUCTION GOOD MANUFACTURING PRACTICES

Qualified Persons in the Pharmaceutical Industry. Code of Practice. March 2008

Good Documentation Practice Session 2

GLP Computerized Systems Updates from OECD Guidance. Dr. Michael Regehr, BASF Corporation 28 JAN 2016, NAICC, Orlando

CHAPTER 5 INFORMATION TECHNOLOGY SERVICES CONTROLS

Could Poor Temperature Data Management be Putting Your GxP Facility at Risk for Data Integrity Violations? we prove it.

GCP Basics - refresher

Guidance for Industry - Computerized Systems Used in Clinical Trials

EUROPEAN COMMISSION ENTERPRISE AND INDUSTRY DIRECTORATE-GENERAL. EudraLex The Rules Governing Medicinal Products in the European Union

ISPE-FDA 3 rd Annual CGMP Conference 2 4 June 2014 Baltimore, MD. Detecting GMP Data Integrity Issues

Discussion Paper on the Validation of Pharmacovigilance Software provided via SaaS

PROPOSED NEW SECTIONS FOR WHO GOOD MANUFACTURING PRACTICES (GMP): MAIN PRINCIPLES FOR PHARMACEUTICAL PRODUCTS DRAFT FOR COMMENT

COMPUTERIZED SYSTEM VALIDATION

Introduction to 21 CFR 11 - Good Electronic Records Management

External Supplier Control Obligations. Records Management

Use of computerised equipment, software and systems in clinical research

New Data Integrity Regulations and Practical Advice for Life Science Laboratories. we prove it.

Deficiencies found in Inspections and QP Responsibilities

Paperless recorders and 21 CFR part 11 compliance Videographic recorders

The Role of the LMS in 21 CFR Part 11 Compliance

VOLUME 4 Good manufacturing practices ANNEX 13 Manufacture of investigational medicinal products JULY 2003

No. Question Answer IT Qualification Statement 1 SITE CONTACT

Transcription:

EUROPEAN COMMISSION HEALTH AND CONSUMERS DIRECTORATE-GENERAL Public Health and Risk Assessment Pharmaceuticals Brussels, SANCO/C8/AM/sl/ares(2010)1064599 EudraLex The Rules Governing Medicinal Products in the European Union Volume 4 Good Manufacturing Practice Medicinal Products for Human and Veterinary Use Annex 11: Computerised Systems Legal basis for publishing the detailed guidelines: Article 47 of Directive 2001/83/EC on the Community code relating to medicinal products for human use and Article 51 of Directive 2001/82/EC on the Community code relating to veterinary medicinal products. This document provides guidance for the interpretation of the principles and guidelines of good manufacturing practice (GMP) for medicinal products as laid down in Directive 2003/94/EC for medicinal products for human use and Directive 91/412/EEC for veterinary use. Status of the document: revision 1 Reasons for changes: the Annex has been revised in response to the increased use of computerised systems and the increased complexity of these systems. Consequential amendments are also proposed for Chapter 4 of the GMP Guide. Deadline for coming into operation: 30 June 2011

Commission Européenne, B-1049 Bruxelles / Europese Commissie, B-1049 Brussel - Belgium Telephone: (32-2) 299 11 11 Principle This annex applies to all forms of computerised systems used as part of a GMP regulated activities. A computerised system is a set of software and hardware components which together fulfill certain functionalities. The application should be validated; IT infrastructure should be qualified. Where a computerised system replaces a manual operation, there should be no resultant decrease in product quality, process control or quality assurance. There should be no increase in the overall risk of the process. General 1. Risk Management Risk management should be applied throughout the lifecycle of the computerised system taking into account patient safety, data integrity and product quality. As part of a risk management system, decisions on the extent of validation and data integrity controls should be based on a justified and documented risk assessment of the computerised system. 2. Personnel There should be close cooperation between all relevant personnel such as Process Owner, System Owner, Qualified Persons and IT. All personnel should have appropriate qualifications, level of access and defined responsibilities to carry out their assigned duties. 3. Suppliers and Service Providers 3.1 When third parties (e.g. suppliers, service providers) are used e.g. to provide, install, configure, integrate, validate, maintain (e.g. via remote access), modify or retain a computerised system or related service or for data processing, formal agreements must exist between the manufacturer and any third parties, and these agreements should include clear statements of the responsibilities of the third party. IT-departments should be considered analogous. 3.2 The competence and reliability of a supplier are key factors when selecting a product or service provider. The need for an audit should be based on a risk assessment. 3.3 Documentation supplied with commercial off-the-shelf products should be reviewed by regulated users to check that user requirements are fulfilled. 3.4 Quality system and audit information relating to suppliers or developers of software and implemented systems should be made available to inspectors on request. Project Phase 4. Validation 4.1 The validation documentation and reports should cover the relevant steps of the life cycle. Manufacturers should be able to justify their standards, protocols, acceptance criteria, procedures and records based on their risk assessment.

4.2 Validation documentation should include change control records (if applicable) and reports on any deviations observed during the validation process. 4.3 An up to date listing of all relevant systems and their GMP functionality (inventory) should be available. For critical systems an up to date system description detailing the physical and logical arrangements, data flows and interfaces with other systems or processes, any hardware and software pre-requisites, and security measures should be available. 4.4 User Requirements Specifications should describe the required functions of the computerised system and be based on documented risk assessment and GMP impact. User requirements should be traceable throughout the life-cycle. 4.5 The regulated user should take all reasonable steps, to ensure that the system has been developed in accordance with an appropriate quality management system. The supplier should be assessed appropriately. 4.6 For the validation of bespoke or customised computerised systems there should be a process in place that ensures the formal assessment and reporting of quality and performance measures for all the life-cycle stages of the system. 4.7 Evidence of appropriate test methods and test scenarios should be demonstrated. Particularly, system (process) parameter limits, data limits and error handling should be considered. Automated testing tools and test environments should have documented assessments for their adequacy. 4.8 If data are transferred to another data format or system, validation should include checks that data are not altered in value and/or meaning during this migration process. Operational Phase 5. Data Computerised systems exchanging data electronically with other systems should include appropriate built-in checks for the correct and secure entry and processing of data, in order to minimize the risks. 6. Accuracy Checks For critical data entered manually, there should be an additional check on the accuracy of the data. This check may be done by a second operator or by validated electronic means. The criticality and the potential consequences of erroneous or incorrectly entered data to a system should be covered by risk management. 7. Data Storage 7.1 Data should be secured by both physical and electronic means against damage. Stored data should be checked for accessibility, readability and accuracy. Access to data should be ensured throughout the retention period. 7.2 Regular back-ups of all relevant data should be done. Integrity and accuracy of backup data and the ability to restore the data should be checked during validation and monitored periodically.

8. Printouts 8.1 It should be possible to obtain clear printed copies of electronically stored data. 8.2 For records supporting batch release it should be possible to generate printouts indicating if any of the data has been changed since the original entry. 9. Audit Trails Consideration should be given, based on a risk assessment, to building into the system the creation of a record of all GMP-relevant changes and deletions (a system generated "audit trail"). For change or deletion of GMP-relevant data the reason should be documented. Audit trails need to be available and convertible to a generally intelligible form and regularly reviewed. 10. Change and Configuration Management Any changes to a computerised system including system configurations should only be made in a controlled manner in accordance with a defined procedure. 11. Periodic evaluation Computerised systems should be periodically evaluated to confirm that they remain in a valid state and are compliant with GMP. Such evaluations should include, where appropriate, the current range of functionality, deviation records, incidents, problems, upgrade history, performance, reliability, security and validation status reports. 12. Security 12.1 Physical and/or logical controls should be in place to restrict access to computerised system to authorised persons. Suitable methods of preventing unauthorised entry to the system may include the use of keys, pass cards, personal codes with passwords, biometrics, restricted access to computer equipment and data storage areas. 12.2 The extent of security controls depends on the criticality of the computerised system. 12.3 Creation, change, and cancellation of access authorisations should be recorded. 12.4 Management systems for data and for documents should be designed to record the identity of operators entering, changing, confirming or deleting data including date and time. 13. Incident Management All incidents, not only system failures and data errors, should be reported and assessed. The root cause of a critical incident should be identified and should form the basis of corrective and preventive actions. 14. Electronic Signature Electronic records may be signed electronically. Electronic signatures are expected to: a. have the same impact as hand-written signatures within the boundaries of the company, b. be permanently linked to their respective record, c. include the time and date that they were applied.

15. Batch release When a computerised system is used for recording certification and batch release, the system should allow only Qualified Persons to certify the release of the batches and it should clearly identify and record the person releasing or certifying the batches. This should be performed using an electronic signature. 16. Business Continuity For the availability of computerised systems supporting critical processes, provisions should be made to ensure continuity of support for those processes in the event of a system breakdown (e.g. a manual or alternative system). The time required to bring the alternative arrangements into use should be based on risk and appropriate for a particular system and the business process it supports. These arrangements should be adequately documented and tested. 17. Archiving Data may be archived. This data should be checked for accessibility, readability and integrity. If relevant changes are to be made to the system (e.g. computer equipment or programs), then the ability to retrieve the data should be ensured and tested. Glossary Application: Software installed on a defined platform/hardware providing specific functionality Bespoke/Customized computerised system: A computerised system individually designed to suit a specific business process Commercial of the shelf software: Software commercially available, whose fitness for use is demonstrated by a broad spectrum of users. IT Infrastructure: The hardware and software such as networking software and operation systems, which makes it possible for the application to function. Life cycle: All phases in the life of the system from initial requirements until retirement including design, specification, programming, testing, installation, operation, and maintenance. Process owner: The person responsible for the business process. System owner: The person responsible for the availability, and maintenance of a computerised system and for the security of the data residing on that system. Third Party: Parties not directly managed by the holder of the manufacturing and/or import authorisation.